Hutchinson-Gilford Syndrome – Progeria Explained
Hutchinson-Gilford Syndrome is an extremely rare genetic disorder causing rapid premature aging in children. Affected children age approximately seven times faster than normal.
Things worth knowing about "Hutchinson-Gilford Syndrome"
Hutchinson-Gilford Syndrome is an extremely rare genetic disorder causing rapid premature aging in children. Affected children age approximately seven times faster than normal.
What is Hutchinson-Gilford Syndrome?
Hutchinson-Gilford Syndrome (HGS), also known as Progeria or Progeria of Childhood, is an exceptionally rare and severe genetic disorder characterized by dramatically accelerated aging. Children affected by this condition develop physical features typical of elderly individuals within the first few years of life. At any given time, only an estimated 350 to 400 children worldwide are living with this disease.
Causes
The condition is caused by a point mutation in the LMNA gene, located on chromosome 1. This gene encodes the protein Lamin A, a key structural component of the nuclear lamina that provides stability to the cell nucleus. The mutation produces a defective, truncated version of Lamin A known as Progerin. Progerin accumulates in the nuclear membrane, disrupts its normal function, and triggers accelerated cellular aging and premature cell death.
In most cases, the mutation arises spontaneously (de novo mutation) and is not inherited from either parent. The condition follows an autosomal dominant inheritance pattern.
Symptoms
Affected children typically appear normal at birth. During the first one to two years of life, characteristic features begin to emerge:
- Severely stunted growth and very low body weight
- Loss of subcutaneous body fat (lipodystrophy)
- Distinctively small face with a disproportionately large head
- Prominent eyes with incomplete eyelid closure
- Small jaw and delayed or absent tooth development
- High-pitched voice
- Loss of scalp and body hair (alopecia)
- Visible veins beneath the skin
- Hardening and thickening of the skin (scleroderma-like changes)
- Joint stiffness and hip dislocations
- Progressive atherosclerosis (hardening of the arteries)
Cognitive development in affected children is typically entirely normal.
Diagnosis
The diagnosis is made clinically based on the characteristic physical features and confirmed by genetic testing (molecular analysis of the LMNA gene). Imaging techniques such as echocardiography and vascular studies are used to assess the extent of cardiovascular involvement. Prenatal diagnosis is theoretically possible when the mutation is known, but is rarely indicated due to the typically spontaneous nature of the mutation.
Treatment
There is currently no cure for Hutchinson-Gilford Syndrome. Treatment is focused on improving quality of life and extending life expectancy.
Pharmacological Therapy
In 2020, Lonafarnib (brand name: Zokinvy) was approved by the US Food and Drug Administration (FDA) as the first drug specifically indicated for the treatment of Progeria. Lonafarnib is a farnesyltransferase inhibitor that reduces the accumulation of Progerin in the nuclear membrane. Clinical studies have demonstrated that Lonafarnib can extend average life expectancy by approximately 2.5 years.
Additional Measures
- Low-dose aspirin to help prevent heart attacks and strokes
- Statins and other medications to manage cardiovascular disease
- Physical therapy to maintain joint mobility
- Nutritional support and counseling to aid weight gain
- Regular cardiological monitoring
Prognosis
Life expectancy in Hutchinson-Gilford Syndrome is severely reduced. The average age of death without treatment is approximately 13 to 14 years. The most common causes of death are heart attack or stroke resulting from progressive atherosclerosis. The introduction of Lonafarnib has statistically improved survival outcomes.
References
- Gordon LB et al. - Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1687-1695.
- Hennekam RC - Hutchinson-Gilford Progeria Syndrome: Review of the Phenotype. American Journal of Medical Genetics Part A. 2006;140A:2603-2624.
- Progeria Research Foundation (PRF) - About Progeria. www.progeriaresearch.org (accessed 2024).
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Hutchinson-Gilford Syndrome-en